BC Platforms (BCP) and US-based Sentieon have announced the launch of a new integrated next generation sequencing (NGS) genetic analytics software, known as BC| Genome X-10. It has been developed specifically for commercial laboratories offering NGS data production-based clinical genetic testing following American College of Medical Genetics (ACMG) guidelines or American Society of Clinical Oncology (ASCO) guidelines. The software provides a full end-to-end solution for commercial laboratories to run highly efficient and automated processes enabling high quality testing serving multiple end customers.
Timo Kanninen, Chief Scientific Officer, BCP, stated: “This solution provides all the necessary tools for configurability in automation, NGS quality metric calculation and approval, extensive panel and variant filtering tools, automated classification of variants and end report layout design. It is a turn-key solution for commercial NGS laboratories with full regulatory compliance. Our solution is available as a complete ready to use deployment from Microsoft Azure providing customers a secure and scalable platform for operating data analysis workflows.”
Brendan Gallagher from Sentieon, commented: "By using Sentieon’s highly scalable and flexible analysis tools, we provide customers with a platform where they can deploy production ready assays quickly and confidently. This happens seamlessly using solutions' configuration capabilities. One is able to maintain full ownership of NGS secondary workflows with traceability and reproducibility, which is typically a key requirement in clinical laboratories.”
Nino da Silva, Deputy Managing Director, BCP, said: "We have seen very positive developments in the market. Both EU countries and the USA Federal government are taking measures at the national level to increase sequencing for COVID-19. This infrastructure will then be available for large predictive and preventive patient driven healthcare initiatives. It is important that countries and regional Healthcare systems use this momentum to establish their own NGS infrastructure to ensure a timely and precise local response with platforms like BC| Genome X-10.”